PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience
PURPOSEPoly (ADP-ribose) polymerase inhibitors (PARPi) have proven efficacy in treatment of BReast CAncer (BRCA) gene mutation-positive platinum-sensitive ovarian cancers. There is paucity of data for their role in platinum-resistant ovarian cancer (PROC). We report here retrospective analysis of ou...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2021-12-01
|
| Colecção: | JCO Global Oncology |
| Acesso em linha: | https://ascopubs.org/doi/10.1200/GO.20.00269 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|